Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Solid Tumors 1 Ovarian Cancer Recurrent 1

Interventions

Paclitaxel 4 liposomal doxorubicin 3 Carboplatin 3 pembrolizumab 2 Bevacizumab 2 1-dodecylpyridoxal 2 poly(I).poly(c12,U) 1 mirabegron 1 disitamab vedotin 1 apatinib 1 anlotinib 1 Tocotrienols 1 Platinum Compounds 1 Lenalidomide 1 Interferon alpha-2 1 Hyperthermic Intraperitoneal Chemotherapy 1 Gemcitabine 1 EP-100 membrane-disrupting peptide 1 Cisplatin 1 AC 7700 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Cancer Recurrent × EP-100 membrane-disrupting peptide × Clear all

NCT01485848 2014-06-10

ESP2011-002

Esperance Pharmaceuticals Inc

Phase 2 Completed

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡